Grape King Bio Ltd
1707.TW
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.65B
Close$
Share Statistics
| Market cap | $12.65 Billion |
|---|---|
| Enterprise Value | $9.45 Billion |
| Dividend Yield | $6.00 (7.03%) |
| Earnings per Share | $8.22 |
| Beta | 0.23 |
| Outstanding Shares | 148,137,000 |
Return
| Return on Equity | 11.21% |
|---|---|
| Return on Assets | 7.65% |
| Return on Invested Capital | 17.54% |
Valuation & Multiples
| P/E Ratio | 11.02 |
|---|---|
| PEG | -79.29 |
| Price to Sales | 1.26 |
| Price to Book Ratio | 1.09 |
| Enterprise Value to Revenue | 0.93 |
| Enterprise Value to EBIT | 4.55 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$1.47
Average shareholder expectationRevenue Estimate
$2.45 B
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$1.62
Average shareholder expectationRevenue Estimate
$2.31 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Grape King Bio Ltd
501 employees
CEO: Sheng-Lin Tseng Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. ...